Hematoma Characteristics and Functional Outcome Do Not Differ in NOAC- Versus VKA-Associated Intracerebral Hemorrhage (P6.060)

Objective: To compare patients with VKA-ICH versus NOAC-ICH regarding baseline characteristics, clinical and radiological findings on admission, mortality and functional outcome. Background: There are only few studies with very low patient numbers comparing the clinical characteristics, radiological findings and functional outcome of patients with non-vitamin-K-antagonist oral anticoagulants (NOACs) compared to vitamin-K(VKA)-associated ICH. Methods: In this monocenter observational study we screened our prospective ICH database for patients with NOAC- and VKA-related ICH between 2008-2015. We compared baseline clinical and radiological parameters between individuals with NOAC- versus VKA-related ICH. Further we assessed functional outcome at 3 months using the modified Rankin scale (mRS). To minimize potential bias by indication we performed a propensity score matching. Results: We identified 17 patients with NOAC- (13/2/2 - Rivaroxaban/Apixaban/Dabigatran) and 95 with VKA-associated ICH. Patients with NOAC-ICH had poorer pre-admission functional status and more often history of ICH compared to VKA-ICH-patients. Baseline clinical status (GCS, NIHSS) as well as radiological findings (ICH-volume and -location, intraventricular involvement, frequency of hematoma expansion) showed no significant differences among both groups. There were no differences in mortality and functional outcome (mRS=0-3/4-6: DOAK 3/14 vs. VKA 27/68; p=0.398). After propensity score matching - adjusting for different baseline characteristics - there were still no differences regarding outcome (mRS=0-3/4-6: DOAK 4/12 vs. VKA 11/27; p=0.515). Conclusions: This analysis provided no evidence of differences in radiological findings or clinical outcome between patients with VKA vs. NOAC-associated ICH. Larger datasets of population-based cohorts or registries may provide further information about whether or not NOAC-ICH differs from VKA-ICH in baseline and outcome findings. Disclosure: Dr. Gerner has nothing to disclose. Dr. Luecking has nothing to disclose. Dr. Koehrmann has nothing to disclose. Dr. Huttner has nothing to disclose.